The Unmet Medical Need
Today, people are enjoying longer, more active lives. This increased activity over a longer lifespan results in more frequent wear and tear on joints, which has caused a staggering rise in chronic discomfort, injuries, and excessive pain associated with musculoskeletal disorders.
Currently, treatments for aging-related musculoskeletal disorders are limited. The first line of treatment typically consists of “conservative” therapies, e.g., physical therapy, visco-supplements such as hyaluronic acid (HA) injections, and anti-inflammatory corticosteroid injections.
When these treatments fail, the last option will be invasive surgical intervention through artificial joint replacement, which many patients are reluctant to embrace. Alternatively, there has been an ongoing search for "regenerative medicine" technologies as an option to either delay or completely avoid the need for joint replacement.
After long-term clinical observation, we discovered a New Molecular Entity (NME) that can slow the progression of degenerative cartilage diseases, including osteoarthritis (OA), while alleviating the associated symptoms and improving patients’ functional outcomes.
We have developed a new injectable formulation of the NME that releases the drug in a controlled manner, providing a sustained drug release benefit.